Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of alemtuzumab after kidney
transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and
to avoid steroids and chronic use of calcineurin inhibitors in pediatric renal transplant
recipients 1 to 20 years of age.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Cooperative Clinical Trials in Pediatric Transplantation